9
Active INDs
4
Technology Platforms
600
Employees

Recent News

Athenex Provides a Corporate Update

Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis

Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis

Athenex, Inc. Reports Fourth Quarter and Year Ended December 31, 2019 Financial Results and Provides Corporate Update

Athenex Announces Participation at the Cowen 40th Annual Health Care Conference

Athenex, Inc. to Report Fourth Quarter and Full Year 2019 Earnings Results on February 27, 2020

Athenex CEO Informs Shareholders of Unrelated Matter Regarding Past Board Membership at Porton Pharma

Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical Through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and Macao

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic Breast Cancer

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
At the 2019 San Antonio Breast Cancer Symposium, Athenex Oncology raised awareness of chemotherapy induced peripheral neuropathy. Visitors performed everyday tasks, while wearing experiential neuropathy gloves.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.